India, Aug. 18 -- BioXcel Therapeutics, Inc. (BTAI) Monday said it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the planned sNDA submission for IGALMI. Following the news, the company's shares were more than 30% up in pre-market.
The FDA feedback confirmed agreement on the content and format for the company's sNDA submission to expand the IGALMI label for the At-Home setting. BioXcel's IGALMI is currently approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.
The company plans to submit sNDA for IGALMI in the first quarter of 2026.
BioXcel stock had closed at $5.48, up 15.37% on Friday. Ithas traded in the range...